X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AL001 (lithium salicylate proline) is an oral small molecule BDNF inhibitor. It is being developed for the treatment of petients with major depressive disorder.
Lead Product(s): Lithium Salicylate Proline
Therapeutic Area: Psychiatry/Psychology Product Name: AL001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
AL001, is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, for the treatment of dementia related to AD, bipolar disorder, MDD, and PTSD.
Lead Product(s): Lithium Salicylate Proline
Therapeutic Area: Psychiatry/Psychology Product Name: AL001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
AL001 is a novel lithium-delivery system; it is a lithium-salicylate-L-proline engineered ionic cocrystal under development as an oral treatment for patients with major depressive disorder, neurological and neuropsychiatric conditions.
Lead Product(s): Lithium Salicylate Proline
Therapeutic Area: Psychiatry/Psychology Product Name: AL001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Details:
AL001 is a novel lithium-delivery system; it is a lithium-salicylate-L-proline engineered ionic cocrystal under development as an oral treatment for patients with bipolar disorder, neurological and neuropsychiatric conditions.
Lead Product(s): Lithium Salicylate Proline
Therapeutic Area: Psychiatry/Psychology Product Name: AL001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
AL001 is a novel lithium-delivery system; it is a lithium-salicylate-L-proline engineered ionic cocrystal under development as an oral treatment for patients with neurodegenerative, neurological and neuropsychiatric conditions.
Lead Product(s): Lithium Salicylate Proline
Therapeutic Area: Psychiatry/Psychology Product Name: AL001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
AL001 is a novel lithium-delivery system; it is a lithium-salicylate-L-proline engineered ionic cocrystal under development as an oral treatment for patients with neurodegenerative, neurological and neuropsychiatric conditions.
Lead Product(s): Lithium Cocrystal
Therapeutic Area: Neurology Product Name: AL001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
ALZN002 is a proprietary active immunotherapy product. It consists of autologous DCs, which are activated WBCs taken from each individual patient that are then engineered outside of the body to attack Alzheimer’s-related amyloid-beta proteins.
Lead Product(s): ALZN002
Therapeutic Area: Neurology Product Name: ALZN002
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
AL001, is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, for the treatment of AD, bipolar disorder, MDD, and PTSD.
Lead Product(s): Lithium Salicylate Proline
Therapeutic Area: Neurology Product Name: AL001
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2023
Details:
AL001, is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline and salicylate, for the treatment of AD, bipolar disorder, MDD, and PTSD.
Lead Product(s): Lithium Salicylate Proline
Therapeutic Area: Psychiatry/Psychology Product Name: AL001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2023
Details:
ALZN002 is a proprietary active immunotherapy product. It consists of autologous DCs, which are activated WBCs taken from each individual patient that are then engineered outside of the body to attack Alzheimer’s-related amyloid-beta proteins.
Lead Product(s): ALZN002
Therapeutic Area: Neurology Product Name: ALZN002
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Biorasi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 04, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
